- Home
- NETD vs RIGL Comparison
NETD vs RIGL Comparison
Compare NETD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NETD
- RIGL
- Stock Information
- Founded
- NETD 2023
- RIGL 1996
- Country
- NETD United States
- RIGL United States
- Employees
- NETD N/A
- RIGL N/A
- Industry
- NETD
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- NETD
- RIGL Health Care
- Exchange
- NETD Nasdaq
- RIGL Nasdaq
- Market Cap
- NETD 417.9M
- RIGL 335.5M
- IPO Year
- NETD 2023
- RIGL 2000
- Fundamental
- Price
- NETD $11.08
- RIGL $21.49
- Analyst Decision
- NETD
- RIGL Buy
- Analyst Count
- NETD 0
- RIGL 5
- Target Price
- NETD N/A
- RIGL $36.40
- AVG Volume (30 Days)
- NETD 178.4K
- RIGL 209.6K
- Earning Date
- NETD 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- NETD N/A
- RIGL N/A
- EPS Growth
- NETD N/A
- RIGL N/A
- EPS
- NETD 0.34
- RIGL 2.08
- Revenue
- NETD N/A
- RIGL $203,077,000.00
- Revenue This Year
- NETD N/A
- RIGL $14.41
- Revenue Next Year
- NETD N/A
- RIGL $15.97
- P/E Ratio
- NETD $32.51
- RIGL $10.38
- Revenue Growth
- NETD N/A
- RIGL 70.16
- 52 Week Low
- NETD $10.53
- RIGL $7.48
- 52 Week High
- NETD $11.11
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- NETD 68.71
- RIGL 64.65
- Support Level
- NETD $11.06
- RIGL $18.63
- Resistance Level
- NETD $11.11
- RIGL $20.99
- Average True Range (ATR)
- NETD 0.02
- RIGL 1.05
- MACD
- NETD 0.00
- RIGL 0.16
- Stochastic Oscillator
- NETD 66.67
- RIGL 89.55
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.